Long-term assessment of glucose control by haemoglobin-AGE measurement

Lancet

Volumn 347, Issue 9000, 1996, Pages 513-515

  Wolffenbuttel, Brace H R ^a   Giordano, Donna ^b   Founds, Henry W ^b   Bucala, Richard ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Alteon Inc   (United States)

^c PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; ERYTHROCYTE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN TREATMENT; MACROMOLECULE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0030024095     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91141-1     Document Type: Article

References (26)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent mellitus. N Engl J Med 1993; 329: 977-86.
2. Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun 1968; 36: 838-43.
3. 1c in normal and diabetic mice: potential model of basement membrane thickening. Proc Natl Acad Sci USA 1975; 72: 3687-91.
4. 1c in diabetes mellitus. N Engl J Med 1976; 295: 417-20.
5. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310: 341-46.
6. Larsen ML, Horder M, Mogensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med 1990; 323: 1021-25.
7. 1c. Clinica Chimica Acta 1983; 134: 317-26.
8. Dunn PJ, Cole RA, Soeldner JS, et al. Temporal relationship of glycosylated haemoglobin concentrations to glucose control in diabetes. Diabetologia 1979; 17: 213-20.
9. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-21.
10. Njoroge FG, Monnier VM. The chemistry of the Maillard reaction under physiological conditions: a review. Prog Clin Biol Res 1989; 304: 85-107.
11. Bucala R, Vlassara H, Cerami A. Advanced glycosylation endproducts: role in diabetic and non-diabetic vascular disease. Drug Develop Res 1994; 32: 77-89.
12. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984; 81: 583-87.
13. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type 1 diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314: 403-08.
14. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediator binding of glucose-modified albumin associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170: 1387-407.
15. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 1992; 89: 2873-77.
16. Bucala R, Makita Z, Vega G, et al. Modification of LDL by advanced glycosylation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441-45.
17. Makita Z, Vlassara H, Rayfield E, et al. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992; 258: 651-53.
18. Wolffenbuttel BHR, Weber RFA, Weeks L, Van Koetsveld PM, Verschhor L. Twice daily insulin therapy in patients with type 2 diabetes in secondary failure to sulphonylureas. Diabetes Res 1990; 13: 79-84.
19. Wolffenbuttel BHR, Sels JPJE, Jungbauer FHW, Menheere PPCA, Nieuwenhuijzen-Krusemn AC. The value of fasting blood glucose and serum fructosamine in the evaluation of metabolic control in NIDDM patients. Diabetes Nutr Metab 1991; 4: 297-303.
20. Diamat Analyzer System, instruction manual. Richmond CA: Bio-Rad Laboratories, 1992.
21. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267: 5133-38.
22. Lowry OH, Rosenbrough NJ, Farr AJ, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
23. Zar JH. Biostatistical analysis. Englewood Cliffs, NJ: Prentice-Hall, 1984.
24. 1c glycated albumin, and fructosamine and analysis of their weight reductions against preceding plasma glucose level. Diabetes Care 1995; 18: 440-47.
25. Peterson CM, Jones RL, Koenig RJ, Melvin ET, Lehrman LL. Reversible hematological sequelae in diabetes mellitus. Ann Intern Med 1977; 86: 425-29.
26. Beisswenger PJ, Makita Z, Curphey TJ, et al. Formation of immunochemical advances glycation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995; 44: 824-29.